In breast cancer cells and non-small cell lung carcinoma cells, MEK–ERK1/2 signaling pathway activation leads to EZH2 overexpression21, while another study demonstrated that downregulation of EZH2 is associated with activation of the Src–Raf–ERK signaling pathway35. The gene discussed is EZH2; the disease is breast carcinoma.